Sunifiram
Ampakine, AMPA-PAM, sub-mg active dose.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Pharmacology
Contents
Related comparisons
Sunifiram vs UnifiramDETAILED OVERVIEW
What is Sunifiram?
Sunifiram (DM-235) is a piperazine-scaffold ampakine showing ~1000× higher in vivo potency than classical pyrrolidone racetams; active dose is in the sub-milligram range. It acts as an AMPA receptor positive allosteric modulator and as an indirect activator at the NMDA glycine site; activates CaMKII + PKC-α signaling pathways → LTP enhancement. Increases acetylcholine release in cerebral cortex. Bell-shaped dose-response curve. Excitotoxicity risk from glutamatergic over-stimulation – avoid high doses + consider NMDA antagonist (e.g. Memantine) co-administration. Tolerance develops within 3-4 days of daily use. Only preclinical data; no human Phase trials.
Mechanism
AMPA-PAM + NMDA-glycine
Half-life
No human data
Legal status
Investigational, not approved
Anecdotal reports describe Sunifiram as a fairly potent nootropic with cognitive enhancement and documented excitotoxicity concerns, leading some users to pair it with an NMDA antagonist such as Memantine. Community accounts report mood enhancement and a slight stimulant-like cognitive boost, with one user reporting effective 5 mg occasional dosing. Another user noted tolerance development after 3 days of continued administration, suggesting cycling is beneficial. Excitotoxic brain injury risk has been reported, so starting at low doses is strongly advised. Some users compare the experience to a megadose of Noopept, producing intense, laser-like focus. Others describe heavily enhanced mood, visual clarity, and cognitive flexibility. The toxicity profile is not fully understood, so caution is essential.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- NMDA glycine siteModerate
- CaMKII / PKCαModerate
- AMPA receptors (indirect)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Limited human safety data: only preclinical (animal) and anecdotal user reports
- Rapid tolerance development, often after just 3-4 days of daily use
- Overstimulation, anxiety, irritability and restlessness from glutamatergic stimulation
- Headache and cholinergic-type symptoms (e.g. nausea) linked to increased acetylcholine release
- Sleep disturbance and agitation (stimulant-like effect per anecdotal reports)
- Theoretical excitotoxicity risk at high doses due to glutamatergic (AMPA/NMDA) overactivation
- Unknown long-term safety, incomplete toxicity profile
Contraindications · 5
- Pregnancy and breastfeeding: safety not established, avoid
- Epilepsy or lowered seizure threshold: glutamatergic overstimulation may theoretically increase seizure risk
- Avoid combining with other glutamatergic/stimulant agents and high doses due to excitotoxicity risk
- Caution in anxiety disorders or sleep problems due to stimulant-like effect
- Not an approved drug, unauthorised everywhere; experimental research chemical, not recommended without clinical supervision
Related Nootropics
Same therapeutic category
FAQ
FAQ
Sunifiram is a so-called ampakine compound developed to enhance memory and learning, described as far more potent than traditional racetams like piracetam. It targets a specific brain signaling system to try to boost communication between nerve cells. There is little human data on it, it is largely an experimental compound used within nootropic communities.
Telegram
Have a question about Sunifiram?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.